SEC Form 3 · accession 0001209191-18-050101
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis McLoughlin
Officer — Chief Commercial Officer
Period of report
Aug 29, 2018
Accepted (ET)
Sep 7, 2018 · 4:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 14,833 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $33.10 | holding | — | — | — | — | Jul 3, 2028 | Common Stock | 20,000 | — | D |
| Stock Option (Right to Buy)F2 | $38.35 | holding | — | — | — | — | Jun 13, 2028 | Common Stock | 47,250 | — | D |
| Stock Option (Right to Buy)F2 | $44.20 | holding | — | — | — | — | Jun 14, 2027 | Common Stock | 6,000 | — | D |
| Stock Option (Right to Buy)F2 | $44.10 | holding | — | — | — | — | Jun 2, 2027 | Common Stock | 10,000 | — | D |
| Stock Option (Right to Buy)F2 | $41.90 | holding | — | — | — | — | Feb 2, 2027 | Common Stock | 3,000 | — | D |
| Stock Option (Right to Buy)F2 | $32.35 | holding | — | — | — | — | Dec 7, 2026 | Common Stock | 6,000 | — | D |
| Stock Option (Right to Buy)F2 | $40.34 | holding | — | — | — | — | Jun 15, 2026 | Common Stock | 2,400 | — | D |
| Stock Option (Right to Buy)F2 | $79.43 | holding | — | — | — | — | Jun 3, 2025 | Common Stock | 3,500 | — | D |
| Stock Option (Right to Buy)F3 | $56.32 | holding | — | — | — | — | Jan 3, 2024 | Common Stock | 10,623 | — | D |
Explanation of responses
- F1Includes 11,162 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 437 restricted stock units that vest on June 3, 2019, (ii) 600 restricted stock units that vest in two equal annual installments on June 3, 2019 and June 3, 2020, (iii) 2,250 restricted stock units that vest in three equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021, and (iv) 7,875 restricted stock units that vest in four equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021 and June 3, 2022, in each case provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- F2The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
- F3The stock options are fully vested.